Skip to content
DAT Supply Log in
DAT Supply Nutraceutical manufacturing
Start your project
Manufacturing / Tablets

Tablets — compressed formats for clinical-style daily-use ranges.

Hard tablets for broad active ranges. Compression profile, coating and pack format are reviewed up front.

Request Quote Talk to our team
Format
Compressed tablet
Coating
Uncoated · Film-coated
Routes
Semi-custom · Custom
Tablets — compressed formats for clinical-style daily-use ranges. — DAT Supply manufacturing
Working routes
3

white-label · semi-custom · custom.

Project gates
4

brief · spec · artwork · release.

Pathways
EU · UK · US

reviewed per target-market framework.

View as private-label format →

Format manifest

Tablets are reviewed per feasibility — compression, coating, taste-mask and pack format are confirmed before any spec lock.

Tablets at a glance
Format
Compressed
Coating
Uncoated · Film-coated
Routes
Semi-custom · Custom
Gates
Brief · Spec · Artwork · Release
Best-fit use cases

When a tablet fits

Tablets fit ranges that need a clinical-style daily-use SKU, a robust shelf life, or a pharmacy-channel presentation.

Manufacturing capability

How tablets are compressed

Tablets are direct-compression or granulated solid-dose SKUs built from actives, fillers (microcrystalline cellulose, dicalcium phosphate, lactose), binders, disintegrants (croscarmellose, sodium starch glycolate), flow aids and lubricants. The blend is fed into a rotary press and compressed at a controlled force to form a tablet of repeatable hardness, friability and dissolution profile. Coating sits on top — uncoated tablets read clinical and budget-efficient; film coatings (HPMC, polyvinyl alcohol) deliver swallowability, taste-masking and a colour story; enteric coatings protect acid-sensitive actives or delay release into the small intestine. Standard sizes run round 8-13 mm and oblong caplets up to 19 mm; the size envelope is driven by the fill weight and the active bulk density. Payload is wide — multivitamin and mineral stacks at clinical doses, single-active high-strength SKUs (vitamin C, magnesium, calcium, iron), botanical extracts and amino acids. Effervescent tablets are a separate sub-format with their own acid-bicarbonate system. Brands choose tablets when shelf life matters (the format is the most stable supplement shape), when pharmacy-channel presentation needs a clinical read, or when high-volume daily-use economics favour the format over a capsule.

Launch routes

Pick the route that matches the brief.

Every project moves through one of three routes. Final routing is confirmed inside the portal — the route shapes the documentation set and the timeline.

01 · White-label

Reviewed concept, brand artwork.

Pick a reviewed pectin-gummy concept from the catalogue and adapt brand artwork. The fastest path from brief to launch — packaging, claims and documentation are reviewed against the target market.

Best for
First gummy SKU · short timelines
Lead time
Confirmed in the quote
Start with this route 02 · Semi-custom

Adjusted within an existing matrix.

Adjust dose, flavour or active stack within an existing matrix. Differentiate the SKU without a full custom-development cycle. Documentation route follows the same project gates.

Best for
Differentiated SKU · existing brand
Lead time
Confirmed in the quote
Start with this route 03 · Custom

Bespoke formulation and dieline.

Fully bespoke formulation, custom flavour profile and packaging dieline. The right route for category-defining launches with longer planning windows and committed quantities.

Best for
Category-defining launch · committed quantities
Lead time
Confirmed in the quote
Start with this route
Working routes in detail

What each route looks like for tablets

White-label

White-label availability is reviewed per project. Compression, coating and pack format sit inside the spec, so true white-label is typically limited to canonical reviewed concepts where the brand can adopt the spec directly. DAT confirms in the brief.

Semi-custom

Semi-custom is the typical tablet route: a reviewed compression profile adjusted for the brand — dose tier, coating colour, shape, pack format and active swaps within compatible chemistry. First runs land at the 2,500-unit MOQ tier and DAT confirms feasibility before spec lock.

Custom

Custom tablet development covers novel actives, multi-layer tablets, enteric or modified-release coatings, and bespoke shapes or debossing. First runs land at the 5,000-unit MOQ tier and timelines are confirmed per project after the compression feasibility review.

Packaging options

PET bottle · Blister · Doypack

Pack format is confirmed per project — bottle, blister and pouch are routinely reviewed.

Tablet packaging is reviewed against the channel. PET bottle is canonical for daily-use ranges — 30, 60 or 90-day counts, child-resistant or standard caps, induction-sealed liners and a tamper-evident outer where the channel calls for it. Blister packs (PVC, PVDC or aluminium-aluminium for moisture-sensitive actives) suit pharmacy-channel SKUs and high-strength single-active formats. Doypack reads DTC-first and lowers secondary packaging. Effervescent tablets ship in tube formats with desiccant closures. Across all options, desiccant inclusion, outer carton and shipping configuration are reviewed in the brief.

  1. PET bottle

    Canonical supplement-shelf format.

  2. Blister

    Pharmacy-channel premium presentation.

  3. Doypack

    Lower-footprint pouch for DTC ranges.

Packaging considerations
  • PET bottle (30/60/90-day)
  • Blister pack (PVC / Alu-Alu)
  • Doypack with resealable zip
  • Effervescent tube
  • Desiccant inclusion
  • Tamper-evident induction seal
  • Outer carton or shipper
  • On-pack QR / batch code
Documentation route

Project gates, not promises

DAT releases documentation as the project moves through each gate. Batch-release documents are issued after production and QC release.

  1. 01
    Stage
    Brief review
    Reviewed

    Target market, format, quantity, claims direction

    When

    Project entry

    Receives

    Feasibility view + working route confirmation

  2. 02
    Stage
    Formula & spec confirmation
    Reviewed

    Formulation route, allergen statement, per-SKU specification

    When

    After brief sign-off

    Receives

    Specification draft + spec-locked formula

  3. 03
    Stage
    Artwork & label review
    Reviewed

    Dieline, on-pack copy, claim wording per market framework

    When

    In parallel with spec lock

    Receives

    Reviewed artwork against the target-market framework

  4. 04
    Stage
    Production & QC
    Reviewed

    In-process control plan, stability and QC release rules

    When

    Once spec & artwork are signed off

    Receives

    Production run + in-process control records

  5. 05
    Stage
    Batch-specific documents
    Reviewed

    Per-batch QC, traceability, release-for-shipment

    When

    After production & QC release

    Receives

    Batch-specific Certificate of Analysis + traceability

  6. 06
    Stage
    Repeat order support
    Reviewed

    Forecast review, raw-material lead times, improvement notes

    When

    Per repeat order

    Receives

    Refreshed documentation per project stage

Documentation availability depends on product, market and project stage. The brand owner remains the food business operator and is responsible for final filings in each target market.

Related product concepts

Concepts reviewed for this format

A short pick of reviewed concepts. Final positioning, claims and documentation are reviewed per project.

Explore the full product catalogue →

Reviewed ingredients

Top ingredients reviewed in tablets

Ingredients commonly reviewed for this format in the DAT Supply dossier library. Open a dossier to see dose anchors, working forms and per-format formulation considerations.

Browse all reviewed ingredients →

Solid dosage

Other formats in the solid dosage group

Adjacent manufacturing formats DAT supports. Routing, gates and documentation framework carry across the family.

Browse all manufacturing formats →

Related ingredients

Common actives for this format

Regulatory framework

EU, UK and US documentation for tablets

Tablets are placed as food supplements under EU Directive 2002/46/EC with FIC labelling and Article 13/14 health claims where applicable. UK retained law mirrors this with FSA notification per the target nation. US launches treat the SKU as a dietary supplement under DSHEA with structure-function claims and a supplement facts panel. Tablets sit close to the pharmacy channel in some markets and the brief review confirms placement before spec lock — notified medicinal claims, enteric-release claims and high-strength single-active SKUs all carry additional documentation scrutiny.

Frequently asked questions

  • Is white-label available for tablets?

    Tablets typically route through semi-custom or custom because the compression profile and coating are part of the spec. Confirmed per project.

  • What documentation gates apply?

    Brief review, spec confirmation, artwork review per the target-market framework, and batch-specific Certificate of Analysis after QC release.

  • What is the order of magnitude for a first run?

    Semi-custom starts from 2,500 units; custom development from 5,000 units. Final volumes are confirmed in the quote.

Related

Continue exploring

Other surfaces on this format — private-label framing, related formats and the public-ready catalogue.

Project handoff

Request a tablet quote

Send the brief — DAT will review feasibility, confirm compression and frame the spec lock.

Request Quote Talk to our team
Quick context request

Get manufacturing context

Drop your work email and a member of the DAT team will follow up with the right context for this concept. Project documents, certificates and pricing are released through the project workspace in the DAT portal.

You will receive a short confirmation email. Project documents (specification, batch-specific COA, packaging documents) are released through the project workspace in the DAT portal once a brief is in place.